Bayer flags new blood thinner as $5B-plus opportunityBusiness, R&D, TherapeuticsBayer predicted on Tuesday its experimental drug against dangerous blood clots could make more than 5 billion euros ($5.4 billion) in peak annual sales, as the company seeks to revive a share price that has drawn interest from activist investors. Read more January 10, 2023/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2021/05/Bayer-seeks-approval-of-2-bln-plan-to-limit-Roundup-claims-Reuters-5-19-21.jpg 503 960 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2023-01-10 09:49:012023-01-10 10:45:12Bayer flags new blood thinner as $5B-plus opportunity